
Kala Pharmaceuticals Inc (NASDAQ:KALA) shares are trading higher after the company said it would sell its EYSUVIS and INVELTYS treatments for $60 million.
Kala Pharmaceuticals is selling its commercial portfolio and related intellectual property assets to Alcon. Kala says the company will receive $60 million in an upfront payment and is eligible to receive additional sales-based milestone payments.